Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2025; 17(12): 113639
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113639
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113639
Steatotic liver disease in patients with chronic hepatitis C
Jakub Janczura, Michał Brzdęk, Krystyna Dobrowolska, Collegium Medicum, Jan Kochanowski University, Kielce 25-516, Poland
Michał Brzdęk, Department of Gastroenterology, Medical University of Lodz, Lodz 92-213, Poland
Robert Flisiak, Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok 15-540, Poland
Kinga Brzdęk, Department of Rheumatology and Connective Tissue Diseases, Nicolaus Copernicus Memorial Hospital in Lodz, Lodz 93-513, Poland
Piotr Rzymski, Department of Environmental Medicine, Poznan University of Medical Sciences, Poznań 60-806, Poland
Dorota Zarębska-Michaluk, Department of Infectious Diseases and Allergology, Jan Koch
Author contributions: Janczura J, Flisiak R, and Zarębska-Michaluk D conceived the study design; Janczura J, Dobrowolska K, and Zarębska-Michaluk D acquired the final version of the manuscript; Brzdęk M and Brzdęk K prepared tables and figures; Brzdęk M performed the statistical analysis, prepared manuscript for the submission; all authors contributed to analyzed and interpreted the data, drafted the manuscript, and approved the final version of the manuscript.
Institutional review board statement: This observational, single-center study was conducted following the approval of the Bioethics Committee of Jan Kochanowski University in Kielce (approval No. 57/2024, dated July 25, 2024).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement:
Dataset available upon reasonable request to the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michał Brzdęk, Collegium Medicum, Jan Kochanowski University, aleja IX Wieków Kielc 19A, Kielce 25-516, Poland. michal.brzdek@gmail.com
Received: August 31, 2025
Revised: September 9, 2025
Accepted: November 20, 2025
Published online: December 27, 2025
Processing time: 118 Days and 2.8 Hours
Revised: September 9, 2025
Accepted: November 20, 2025
Published online: December 27, 2025
Processing time: 118 Days and 2.8 Hours
Core Tip
Core Tip: Steatotic liver disease (SLD) is common in patients with chronic hepatitis C and shapes their overall health and treatment journey. In our real-world study, SLD patients were older, had higher body mass index, and carried more metabolic and liver-related risks, leading to lower response rates to antiviral therapy. Yet, SLD itself was not the culprit - other comorbidities were. This highlights that successful treatment depends not only on antivirals but also on managing the broader metabolic and lifestyle factors that impact liver health.